- Регистрация
- 17 Февраль 2018
- Сообщения
- 38 866
- Лучшие ответы
- 0
- Reactions
- 0
- Баллы
- 2 093
Offline
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time in over two decades that the agency has approved a non-opioid pain drug with a novel mechanism of action.
The drug, Journavx (suzetrigine), is an oral pill that treats acute pain, such as from surgery or injuries. Unlike opioids, which work by latching onto receptor proteins on nerves in the central nervous system, suzetrigine works only in peripheral nerves—that is, those outside the brain and spinal cord. Specifically, the drug inhibits a voltage-gated sodium ion channel called 1.8 (NaV1.8) that is known to relay pain signals, but only in peripheral nerves.
Because it works outside the brain by a different mechanism than opioids, the new medication offers a safe alternative to opioids, which can be highly addictive.
Read full article
Comments
The drug, Journavx (suzetrigine), is an oral pill that treats acute pain, such as from surgery or injuries. Unlike opioids, which work by latching onto receptor proteins on nerves in the central nervous system, suzetrigine works only in peripheral nerves—that is, those outside the brain and spinal cord. Specifically, the drug inhibits a voltage-gated sodium ion channel called 1.8 (NaV1.8) that is known to relay pain signals, but only in peripheral nerves.
Because it works outside the brain by a different mechanism than opioids, the new medication offers a safe alternative to opioids, which can be highly addictive.
Read full article
Comments
